参考文献/References:
[1] Semsarian C,Ingles J,Maron MS,et al.New perspectives on the prevalence of hypertrophic cardiomyopathy[J].J Am Coll Cardiol,2015,65(12):1249-1254.
[2] van Velzen HG,Theuns DA, Yap SC,et al.Incidence of device-detected atrial fibrillation and long-term outcomes in patients with hypertrophic cardiomyopathy[J].Am J Cardiol,2017,119(1):100-105.
[3] Guttmann OP, Rahman MS, O’Mahony C,et al.Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy:systematic review[J].Heart,2014,100(6):465-472.
[4] Jung H, Yang PS, Sung JH,et al.Hypertrophic cardiomyopathy in patients with atrial fibrillation:prevalence and associated stroke risks in a nationwide cohort study [J].Thromb Haemost,2019,119(2):285-293.
[5] Hofer D, Steffel J, Hürlimann D,et al.Long-term incidence of inappropriate shocks in patients with implantable cardioverter defibrillators in clinical practice—an underestimated complication?[J].J Interv Card Electrophysiol,2017,50(3):219-226.
[6] Liu Q, Li D, Berger AE,et al.Survival and prognostic factors in hypertrophic cardiomyopathy:a meta-analysis[J].Sci Rep,2017,7 (1):435-451.
[7] Cochet H, Morlon L, Vergé MP,et al.Predictors of future onset of atrial fibrillation in hypertrophic cardiomyopathy[J].Arch Cardiovasc Dis,2018,111(10):591-600.
[8] Klopotowski M, Kwapiszewska A, Kukula K,et al.Clinical and echocardiographic parametres as risk factors fo atrial fibrillation in patients with hypertrophic cardiomyopathy[J].Clin Cardiol,2018,41(10):1336-1340.
[9] Pedrosa RP,Lima SG,Drager LF,et al.Sleep quality and quality of life in patients with hypertrophic cardiomyopathy[J].Cardiology,2010,117(3):200-206.
[10] Prinz C,Bitter T,Oldenburg O,et al.Incidence of sleep disordered breathing in patients with hypertrophic cardiomyopathy[J].Congest Heart Fail,2011,17(1):19-24.
[11] Liu L, Wu L, Zheng L,et al.Associations between multiple circulating biomarkers and the presence of atrial fibrillation in hypertrophic cardiomyopathy with or without left ventricular outflow tract obstruction[J].Intl Heart J,2019,60(2):327-335.
[12] Wang Y, Tang Y, Zou Y,et al.Plasma level of big endothelin-1 predicts the prognosis in patients with hypertrophic cardiomyopathy[J].Int J Cardiol,2017,243:283-289.
[13] Tuluce K,Yakar Tuluce S,Kahya Eren N,et al.Predictors of future atrial fibrillation development inpatients with hypertrophic cardiomyopathy:a prospective follow-up study[J].Echocardiography,2016,33(3):379-385.
[14]Nielsen JB,Graff C,Pietersen A,et al.J-shaped association between QTc interval duration and the risk of atrial fibrillation:results from the Copenhagen ECG study[J].J Am Coll Cardiol,2013,61(25):2557-2564.
[15]?etin M,Kocaman SA,Erdo?an T,et al.Fragmented QRS may predict postoperative atrial fibrillation in patients undergoing isolated coronary artery bypass graft surgery[J].Anadolu Kardiyol Derg,2012,12(7):576-583.
[16] 闻松男,刘念,宁曼,等.校正的QT间期延长独立预测肥厚型心肌病合并心房颤动患者导管消融术后复发[J].中国心脏起搏与心电生理杂志,2016,30(2):102-106.
[17] 李邦合,万海伟,董鹏,等.碎裂QRS波对肥厚型心肌病伴心房颤动患者导管消融术后复发的预测价值[J].中国医药导报,2019,16(21):181-184.
[18] Debonnaire P, Joyce E, Hiemstra Y,et al.Left atrial size and function in hypertrophic cardiomyopathy patients and risk of new-onset atrial fibrillation[J].Circ Arrhythm Electrophysiol,2017,10(2):e004052.
[19] Vasquez N, Ostrander BT, Lu DY,et al.Low left strain is associated with adverse outcomes in hypertrophic cardiomyopathy patients[J].J Am Soc Echocardiogr,2019,32(5):593-603.
[20]冯坤,赵春霞,熊峰,等.超声心动图在肥厚型心肌病中的诊疗进展[J].心血管病学进展,2016,37(4):409-412.
[21] Costabel JP, Galve E, Terricabras M,et al.E/e’ ratio and left atrial area are predictors of Atrial fibrillation in patients with hypertrophic cardiomyopathy[J].Echocardiography,2018,35(7):935-940.
[22] Siontis KC,Geske JB,Ong K,et al.Atrial fibrillation in hypertrophic cardiomyopathy:prevalence,clinical correlations,and mortality in a large high-risk population[J].J Am Heart Assoc,2014,25;3(3):e001002.
[23] Lu DY,Hailesealassie B,Ventoulis I,et al.Impact of peak provoked left ventricular outflow tract gradients on clinical outcomes in hypertrophic cardiomyopathy[J].Int J Cardiol,2017,243:290-295.
[24] Lee SE,Park Jk,Uhm JS,et al.Impact of atrial fibrillation on the clinical course of apical hypertrophic cardiomyopathy[J].Heart,2017,103(19):1496-1501.
[25] Kao YC, Hung MJ.Echocardiographic evaluation of left atrial function to discriminate non-valvulaer atrial fibrillation development in patients with apical hypertrophic cardiomyopathy[J].Acta Cardiol Sin,2020,36(1):33-43.
[26] Marrouche NF,Wilber D,Hindricks G, et al .Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation:the DECAAF study[J].JAMA,2014,311(5):498-506.
[27]Fochler F, Yamaguchi T, Kheirkahan M,et al.Late gadolinium enhancement magnetic resonance imaging guided treatment of post-atrial fibrillation ablation recurrent arrhythmia[J].Circ Arrhythm Electrophysiol,2019,12(8):e007174.
[28]Latif SR, Nguyen VQ, Peters DC,et al.Left atrial fibrosis correlates with?extent of?left ventricular myocardial delayed enhancement and?left ventricular strain in?hypertrophic cardiomyopathy[J].Int J Cardiovasc Imaging,2019,35(7):1309-1318.
[29]Sivalokanathan S, Zghaib T, Greenland GV,et al.Hypertrophic cardiomyopathy patients with paroxysmal atrial fibrillation have a high burden of left atrial fibrosis by cardiac magnetic resonance imaging[J].JACC Clin Electrophysiol,2019,5(3):364-375.
[30] Maron BJ,Haas TS,Maron MS,et al.Left atrial remodeling in hypertrophic cardiomyopathy and susceptibility markers for atrial fibrillation identified by cardiovascular magnetic resonance[J].Am J Cardiol,2014,113(8):1394-1400.
[31]Farhad H,Seidelmann SB,Vigneault D,et al.Left atrial structure and function in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy[J].J Cardiovasc MagnReson,2017,19(1):107.
[32] Ho CY, Day SM, Ashley EA,et al.Genotype and lifetime burden of disease in hypertrophic cariomyopathy: insig hts from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)[J].Circulation,2018,138(14):1387-1398.
[33] Lee SP, Ashley EA, Homburger J,et al.Incident atrial fibrillation is associated with MYH7 sarcomeric gene variation in hypertrophic cardiomyopathy[J].Circ Heart Fail,2018,11(9):e005191.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(12):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(12):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(12):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(12):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(12):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(12):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(12):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]冯坤,刘春霞,熊峰,等.超声心动图在肥厚型心肌病诊治中的应用进展[J].心血管病学进展,2016,(4):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
FENG Kun,LIU Chunxia,XIONG Feng,et al.Progress in Application of Echocardiography in
Diagnosis and Treatment of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2016,(12):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
[9]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(12):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[10]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(12):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[11]邓清文,何森.肥厚型心肌病合并心房颤动的研究进展[J].心血管病学进展,2021,(4):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
DENG Qingwen,HE Sen.Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(12):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
[12]李珂 赵海娟 赵耀 黄松群 郭志福.肥厚型心肌病合并心房颤动的导管消融[J].心血管病学进展,2022,(5):399.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.004]
LI Ke,ZHAO Haijuan,ZHAO Yao,et al.Catheter Ablation of Hypertrophic Cardiomyopathy with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2022,(12):399.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.004]
[13]余淼 汤宝鹏.肥厚型心肌病合并心房颤动非药物治疗研究进展[J].心血管病学进展,2024,(1):40.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.011]
YU Miao,TANG Baopeng.Non-Pharmacological Treatment of Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2024,(12):40.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.011]